A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3023703 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 21 Dec 2018
At a glance
- Drugs LY 3023703 (Primary) ; Celecoxib
- Indications Acute pain; Dental pain; Musculoskeletal pain
- Focus Adverse reactions
- Sponsors Eli Lilly
- 01 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 27 Nov 2013 Planned End Date changed from 1 Oct 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 30 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.